Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data

INTRODUCTION: The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study showed that compared with placebo, canagliflozin 100 mg significantly reduced the risk of major cardiovascular events and adverse renal outcomes in patients with diabetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Willis, Michael, Asseburg, Christian, Slee, April, Nilsson, Andreas, Neslusan, Cheryl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547928/
https://www.ncbi.nlm.nih.gov/pubmed/32930969
http://dx.doi.org/10.1007/s13300-020-00923-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547928/
https://www.ncbi.nlm.nih.gov/pubmed/32930969
http://dx.doi.org/10.1007/s13300-020-00923-w

Ejemplares similares